Analytical Data
-
Gene name
RAGE
- Application
-
Alternative Names
RAGE；RAGE；Advanced glycosylation end product-specific receptor
-
Species
Mouse
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q62151-1
-
Expression Region
1-342aa
-
AA Sequence
MPAGTAARAW VLVLALWGAV AGGQNITARI GEPLVLSCKG APKKPPQQLE WKLNTGRTEA WKVLSPQGGP WDSVARILPN GSLLLPATGI VDEGTFRCRA TNRRGKEVKS NYRVRVYQIP GKPEIVDPAS ELTASVPNKV GTCVSEGSYP AGTLSWHLDG KLLIPDGKET LVKEETRRHP ETGLFTLRSE LTVIPTQGGT HPTFSCSFSL GLPRRRPLNT APIQLRVREP GPPEGIQLLV EPEGGIVAPG GTVTLTCAIS AQPPPQVHWI KDGAPLPLAP SPVLLLPEVG HEDEGTYSCV ATHPSHGPQE SPPVSIRVTE TGDEGPAEGS VGESGLGTLA LA
-
Molecular Weight
35 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
RAGE (Receptor for Advanced Glycation End Products) is a multi-ligand receptor belonging to the immunoglobulin superfamily, primarily expressed in inflammatory and vascular tissues. Its role has been extensively studied in the context of various diseases, including diabetes, Alzheimer's disease, and cardiovascular disorders. RAGE is known to interact with a range of endogenous and exogenous ligands, facilitating the progression of inflammation and oxidative stress. The receptor is implicated in the pathogenesis of chronic diseases, where its activation triggers signaling cascades that exacerbate tissue damage and disease severity. Recent research has focused on the potential of RAGE as a therapeutic target. The study of RAGE recombinant proteins aims to enhance our understanding of its structure, function, and interaction with ligands, which could lead to the development of novel therapeutic strategies. By investigating the recombinant forms of RAGE, researchers seek to decipher its molecular mechanisms, optimize its inhibition, and explore its utility in drug design and delivery systems. The ongoing exploration of RAGE and its recombinant variants continues to shed light on its complex role in human health, paving the way for innovative approaches to manage diseases associated with RAGE dysregulation.
